Current Vaccines News and Events | Page 25

Current Vaccines News and Events, Vaccines News Articles.
Sort By: Most Relevant | Most Viewed
Page 25 of 25 | 1000 Results
New HPV approved after international phase 2/3 trial involving Moffitt Cancer Center
A pivotal international phase 2/3 clinical trial involving Moffitt Cancer Center faculty demonstrated that vaccination with Gardasil 9 protects against nine HPV types, seven of which cause most cases of cervical, vulvar, and vaginal disease. The trial data indicate that if populations are vaccinated with Gardasil 9 approximately 90 percent of all cervical cancers worldwide can be prevented. (2015-02-20)

New test to predict the effectiveness of cancer vaccines
Many therapeutic cancer vaccines that are currently being developed are designed to direct the immune system against altered cancer-cell proteins. However, these vaccines can only be effective if the tumor cells present the altered protein to the immune system in a perfectly matching shape. Scientists from the German Cancer Research Center and Heidelberg University Hospital have now described a test to predict whether this prerequisite for effective tumor vaccination is fulfilled. (2015-02-19)

Needle-free vaccination: How scientists ask skin cells for help
New research published in the January 2015 issue of Experimental Dermatology introduces a new approach to stimulate the skin immune response by applying needle-free vaccination. (2015-02-18)

NIH-sponsored HIV vaccine trial launches in South Africa
A clinical trial has launched in South Africa to study an investigational HIV vaccine regimen for safety and the immune responses it generates in volunteers. This experimental regimen is based on the one tested in the RV144 trial - -the first to demonstrate that a vaccine can protect people from HIV infection -- but is designed to potentially provide greater protection and is adapted to the predominant HIV subtype in southern Africa. (2015-02-18)

Seasonal flu vaccine induces antibodies that protect against H7N9 avian flu
Antibodies that protect against H7N9 avian flu, which emerged in China in 2013 and sparked fears of a global pandemic, have been isolated in individuals who received seasonal flu vaccinations. These antibodies account for a small percentage of the total immune response, but appear to broadly neutralize H7 viruses and represent promising new targets for therapeutic development against a wide range of influenza strains. (2015-02-17)

Lighting up a new path for novel synthetic polio vaccine
Scientists from the UK and USA are using technology that helped in the design of a new synthetic vaccine to combat the foot and mouth disease virus to target the virus that causes polio. The vaccine for FMDV does not contain the viral genome but instead 'mimics' the structure of the live virus. This project is being funded by a £438,000 grant from the World Health Organisation and Bill & Melinda Gates Foundation. (2015-02-13)

HPV vaccination not linked to riskier sex
Receiving the HPV vaccine does not increase rates of sexually transmitted infections in adolescent females, suggesting that vaccinating girls is not likely to promote unsafe sexual activity. (2015-02-09)

Pediatric Infectious Diseases Society issues statement on measles outbreak
The Pediatric Infectious Diseases Society, an organization of physicians, scientists, and other medical professionals dedicated to treating and preventing infectious diseases, issued a statement today about the ongoing measles outbreak, urging vaccination to halt the spread of the disease and to prevent future outbreaks. (2015-02-06)

Children who get vitamin A may be less likely to develop malaria
Children under age 5 living in sub-Saharan Africa were 54 percent less likely to develop malaria if they had been given a single large dose of vitamin A, new research led by the Johns Hopkins Bloomberg School of Public Health suggests. (2015-02-03)

News from Annals of Internal Medicine tip sheet, Feb. 3, 2015
This release includes summaries of articles being featured in the next issue of Annals of Internal Medicine, including 'Oral supplements help to heal bed sores in malnourished patients', 'Survey suggests shortcomings in end-of-life care' and 'ACIP Releases its Recommended Adult Immunization Schedule for 2015'. (2015-02-02)

Ebola vaccine trial opens in Liberia
A large clinical trial to assess the safety and efficacy of two experimental vaccines to prevent Ebola virus infection is now open to volunteers in Liberia. The trial is being led by a recently formed Liberia-US clinical research partnership and is sponsored by the National Institute of Allergy and Infectious Diseases, part of the NIH. (2015-02-02)

Confidence in government linked to willingness to vaccinate
A new study suggests that confidence in government may play a key role in the public's willingness to get at least some vaccines. (2015-02-02)

Customized soap bubbles set to transform drug and vaccine delivery
At a University of Maryland start-up called SD Nanosciences, scientists are covering soap bubbles with biomolecules that act as a disguise, tricking the body's cells into mistaking the capsule for a bacterium, a cancer cell or almost any other disease-causing cell. Because the technology is flexible, cost-effective and highly efficient, it is drawing a lot of attention from both public and private funders for drug delivery and vaccine production. (2015-01-28)

Study finds rabies booster defends pets with out-of-date vaccination against the disease
A new study by Kansas State University veterinary diagnosticians finds that pets with out-of-date rabies vaccinations are very unlikely to develop the fatal disease if given a rabies booster immediately after exposure to the virus. (2015-01-26)

Toward a cocaine vaccine to help addicts kick the habit
In their decades-long search for vaccines against drugs of abuse, scientists have hit upon a new approach to annul cocaine's addictive buzz. They report in the ACS journal Molecular Pharmaceutics that their strategy, which they tested on mice, harnesses a bacterial protein to trigger an immune system attack on the drug if it enters the body. This response could dull cocaine's psychotropic effects and potentially help users of the drug kick the habit. (2015-01-21)

Breakthrough may impact flu vaccination
An analysis of 10 years' worth of data on human influenza B viruses has shed new light on the pathogen which can cause the seasonal flu. Findings from this study could help make flu immunization programs more effective; by better targeting vaccines or by eventually eliminating one of the flu lineages completely. (2015-01-20)

Bed nets and vaccines: Some combinations may worsen malaria
Combining insecticide-treated bed nets with vaccines and other control measures may provide the best chance at eliminating malaria, which killed nearly 600,000 people worldwide in 2013, most of them African children. (2015-01-19)

Vaccine-induced CD4 T cells have adverse effect in a mouse model of infection
New findings demonstrate that vaccine-elicted CD4 T cells lead to overwhelming inflammatory response in mouse model of chronic infection. (2015-01-15)

One punch to knock out flu
Researchers show that when comparing the potency of an isolated strain-specific flu antibody with an isolated broadly-neutralizing flu antibody in a lab setting, the latter have much weaker neutralization activity than the strain-specific antibodies. (2015-01-14)

TSRI scientists design nicotine vaccine that provokes robust immune response
When a promising nicotine vaccine failed in clinical trials a few years ago, scientists from The Scripps Research Institute were determined to keep trying to help smokers overcome their addiction. Now the team has designed a more effective nicotine vaccine and proven that the structures of molecules used in vaccines is critical. (2015-01-12)

New approach may lead to inhalable vaccines for influenza, pneumonia
Researchers at the University of North Carolina at Chapel Hill and North Carolina State University have uncovered a novel approach to creating inhalable vaccines using nanoparticles that shows promise for targeting lung-specific diseases, such as influenza, pneumonia and tuberculosis. (2015-01-07)

12-year study confirms overall safety of measles vaccines
A 12-year study of two measles-containing vaccines, published today in Pediatrics, found that seven main adverse outcomes were unlikely after either vaccine. (2015-01-05)

HIV vaccines should avoid viral target cells, primate model study suggests
Vaccines designed to protect against HIV have backfired in clinical trials. Non-human primate model studies suggest an explanation. (2015-01-02)

Speeding up Ebola drug production
Researchers at the University of California, Davis will explore ways to speed production of the Ebola drug with a $200,000 rapid-response grant from the National Science Foundation. (2014-12-30)

Study confirms Ebola and Marburg virus DNA vaccines are safe and immunogenic in Africa
Results from the first Ebola vaccine clinical trial conducted in Africa (in 2009-2010) reveal a vaccine candidate produces the same immune response seen in the United States in an African setting. The findings of this 2009-2010 study, published online today in The Lancet, describe the successful execution and analysis of a Phase 1 clinical trial of two DNA vaccine candidates, one for the Ebola virus and the other for the closely related Marburg virus. (2014-12-23)

Scientists report on trial of early-generation Ebola, Marburg vaccine candidates
esults of an early-stage clinical trial of two experimental vaccines against Ebola and Marburg viruses -- the first to be completed in an African country -- showed that they were safe and induced immune responses in healthy Ugandan adult volunteers. (2014-12-23)

The Lancet: Trial confirms Ebola vaccine candidate safe and equally immunogenic in Africa
Two experimental DNA vaccines to prevent Ebola virus and the closely related Marburg virus are safe, and generated a similar immune response in healthy Ugandan adults as reported in healthy US adults earlier this year. The findings, from the first trial of filovirus vaccines in Africa, are published in The Lancet. (2014-12-22)

High-dose flu vaccine appears better for frail older adults in long-term care
For frail older adults living in long-term care facilities, the high-dose influenza vaccine appears to be a better option than the regular shot, producing a stronger immune response than the standard vaccine, according to a study published in The Journal of Infectious Diseases and now available online. High-dose vaccine may play a key role, along with improving vaccination rates among health care workers and other strategies, in preventing flu in this vulnerable and growing population. (2014-12-18)

Ebola virus may replicate in an exotic way
University of Utah researchers ran biochemical analysis and computer simulations of a livestock virus to discover a likely and exotic mechanism to explain the replication of related viruses such as Ebola, measles and rabies. The mechanism may be a possible target for new treatments within a decade. (2014-12-11)

Scientists closing in on an new type of vaccine
When we acquire diarrhea on a vacation, it is often caused by a bacterial infection. Now a Danish research team is working on a new type of vaccine design targeting the disease causing bacterium -- if it works it may very well revolutionize not only the prevention of this disease, but also offer protection against other pathogens with a heavy disease burden such as Mycobacterium tuberculosis and antibiotic-resistant Staphylococcus aureus (MRSA). The project is supported with a 2.93 million DKK Novo Pre-Seed grant (393.677 €) from Novo Seeds, which is part of the Novo Nordisk Foundation and Novo A/S as well as the University of Southern Denmark's internal Proof of Concept Board. (2014-12-11)

Study of malaria parasites receives 4-year NIH grant of up to $1.8 million
The National Institutes of Health awarded Texas Biomedical Research Institute staff scientist Ian Cheeseman, Ph.D., over $450,000 in first-year funding and is expected to receive up to $1.8 million over four years to continue research into a new method for sequencing the genomes of individual malaria parasites. (2014-12-09)

Dartmouth/Univ. of Exeter Study: Correcting myths about the flu vaccine
Correcting myths about vaccines may not be the most effective approach to promoting immunization among vaccine skeptics according to a recent Dartmouth College -- University of Exeter study, as reported in a new article in the journal Vaccine. (2014-12-08)

Parasite researcher wins international malaria medal
Melbourne researcher professor Alan Cowman has won the Sornchai Looareesuwan Medal 2014 for his significant contributions to understanding how the malaria parasite causes disease and for his search for potential malaria vaccines. (2014-12-03)

Human antibodies produced in DNA-vaccinated cows protect in lethal models of hantavirus
Scientists investigating the potentially deadly hantavirus have used a novel approach to developing protective antibodies against it. The research, published in Science Translational Medicine, used specially bred 'transchromosomal' cows engineered to produce fully human antibodies. Investigators immunized the cows with DNA vaccines targeting two types of hantaviruses, Andes and Sin Nombre. The team collected plasma from the cows, purified the human IgG antibodies, and tested the material, which had potent neutralizing activity against both hantaviruses. (2014-11-26)

Vaccines may make war on cancer personal
In the near future, physicians may treat some cancer patients with personalized vaccines that spur their immune systems to attack malignant tumors. New research led by scientists at Washington University School of Medicine in St. Louis has brought the approach one step closer to reality. (2014-11-26)

A hybrid vehicle that delivers DNA
A new hybrid vehicle is under development. Its performance isn't measured by the distance it travels, but rather the delivery of its cargo: vaccines that contain genetically engineered DNA to fight HIV, cancer, influenza and other maladies. Described in the Proceedings of the National Academy of Sciences, the technology could help unleash the potential of DNA vaccines, which despite two decades of research, have yet to make a significant impact in the treatment of major illnesses. (2014-11-25)

Powdered measles vaccine found safe in early clinical trials
A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published Nov. 28 in the journal Vaccine. The paper is now available online. (2014-11-25)

Study finds provider-focused intervention improves HPV vaccination rates
Changing the way doctors practice medicine is difficult, however a new study has shown that combining traditional education with quality improvement and incentives improves Human Papilloma virus vaccination rates in boys and girls. The study, which appears on-line in the journal Vaccine, has the potential to produce sustained improvements in these vaccination rates. (2014-11-24)

Possibilities for personalized vaccines revealed at ESMO symposium
The possibilities for personalized vaccines in all types of cancer are revealed today at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland. (2014-11-21)

When vaccines are imperfect
The control of certain childhood diseases is difficult, despite high vaccination coverage in many countries. One of the possible reasons for this is 'imperfect vaccines,' that is, vaccines that fail either due to 'leakiness,' lack of effectiveness on certain individuals in a population, or shorter duration of potency. In a paper publishing today in the SIAM Journal on Applied Mathematics, Felicia Magpantay et al. use a mathematical model to determine the consequences of vaccine failure and resulting disease dynamics. (2014-11-20)

Page 25 of 25 | 1000 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.